Center Laboratories, Inc. - May 20, 2020 Form 4 Insider Report for WINDTREE THERAPEUTICS INC /DE/ (WINT)

Role
10%+ Owner
Signature
/s/ Lin, Jung-Chin
Stock symbol
WINT
Transactions as of
May 20, 2020
Transactions value $
$2,382,538
Form type
4
Date filed
1/10/2022, 04:03 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WINT Common Stock Other $0 -3.55M -75% $0.00 1.18M May 20, 2020 By Bioengine Capital Inc. F1, F2
transaction WINT Common Stock Purchase $400K +55.2K +4.66% $7.25 1.24M May 20, 2020 By Bioengine Capital Inc. F2
transaction WINT Common Stock Purchase $1.98M +1.24M $1.60 1.24M Dec 30, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WINT SERIES F WARRANTS Other $0 0 $0.00* 0 Jun 24, 2020 Common Stock 385K $3.68 By Bioengine Capital Inc. F4
transaction WINT SERIES G WARRANTS Other $0 -249K -50% $0.00 249K May 20, 2020 Common Stock 249K $12.15 By Bioengine Capital Inc. F5, F6, F7
transaction WINT SERIES J WARRANTS Purchase $0 +55.2K $0.00 55.2K May 20, 2020 Common Stock 55.2K $7.80 By Bioengine Capital Inc. F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Center Laboratories, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Reporting Person voluntarily discloses that, on May 20, 2020, the Issuer effected a 1-for-3 reverse stock split of its Common Stock (the "Reverse Stock Split"), which resulted in the Reporting Person's beneficial ownership of issued and outstanding Common Stock being reduced from 3,551,750 shares of Common Stock to 1,183,916 shares of Common Stock. The shares of Common Stock are directly held by Bioengine Capital Inc., and indirectly held by the Reporting Person, which owns 58.6% of Bioengine Capital Inc.
F2 The shares of Common Stock are directly held by Bioengine Capital Inc, and indirectly held by the Reporting Person, which owns 58.6% of Bioengine Capital Inc.
F3 On December 30, 2021, the Reporting Person purchased all remaining shares of Common Stock held by Bioengine Capital Inc., and now holds the shares directly.
F4 The Reporting Person voluntarily discloses that, on July 24, 2020, Series F Warrants had expired. The Series F Warrants were directly held by Bioengine Capital Inc. and indirectly held by the Reporting Person, which owns 58.6% of Bioengine Capital Inc. As a result, the Reporting Person currently indirectly owns 0 shares of Series F Warrants.
F5 The Reporting Person voluntarily discloses that, on May 20, 2020, in connection with the Reverse Stock Split, the Issuer effected a 1-for-3 reverse split of all of its issued and outstanding Series G Warrants, which resulted in the Reporting Person's beneficial ownership of Series G Warrants being reduced from 747,012 shares of Series G Warrants to 249,004 shares of Series G Warrants.
F6 The Series G and Series J Warrants are directly held by Bioengine Capital Inc. and indirectly held by the Reporting Person, which owns 58.6% of Bioengine Capital Inc.
F7 The exercise of the Series G Warrants is subject to a beneficial ownership limitation of 9.99%, and this limitation can only be changed with effect from the 61st day after a notice requesting such change is delivered to the Issuer.

Remarks:

This filing constitutes a Form 4 exit filing for the Reporting Person, as the Reporting Person is no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended, as a result of the transactions reported herein.